Better Health for All

SciSparc Ltd. is a clinical-stage pharmaceutical company entirely devoted to developing therapies for central nervous system disorders, with 100% of its drug candidates aimed at health improvement.

Phase IIa trials for SCI-110 showed an average 21% tic reduction in Tourette Syndrome patients and a 23% reduction in agitation symptoms in elderly Alzheimer's patients, with patients free of delirium, oversedation, hypotension, or falls. The company is developing SCI-110 for Tourette Syndrome, Alzheimer's disease and agitation, and SCI-210 for autism spectrum disorder, all of which address mental health needs. The company's SCI-110 aims to decrease dosage requirements, side effects, and adverse events compared to Dronabinol, a synthetic THC. Clinical trials for SCI-210 for autism spectrum disorder and SCI-110 for Tourette Syndrome are double-blind, randomized, and placebo-controlled, and have secured Institutional Review Board approvals for all sites. However, the company's clinical trials for SCI-210 and SCI-110 target specific age groups (children aged 5-18 with ASD, adults aged 18-65 with Tourette Syndrome, and elderly Alzheimer's patients), which represents a limited reach to vulnerable populations. Furthermore, the renewal of approval for a clinical trial was for only 30 days, pending final approval from the Israeli police department, indicating potential regulatory scrutiny or delays. The company also relies on forward-looking statements, which involve risks and uncertainties detailed in SEC filings.

Honest & Fair Business

SciSparc Ltd. has all its subsidiaries covered by an independent external audit, which is conducted by Kost Forer Gabbay & Kasierer (EY Global).

The company also has a Code of Ethics and Conduct document available. However, SciSparc received a notification from Nasdaq on January 12, 2026, for non-compliance with the minimum stockholders' equity requirement, reporting approximately $(81,000) as of June 30, 2025, against a $2.5 million requirement. This follows a previous delisting notice in July 2024 for not meeting the minimum bid price requirement, which was resolved by a 1-for-21 reverse share split in July 2025.

Kind to Animals

SciSparc Ltd. is listed as a company that uses animal testing.

There is no evidence of a formal policy to restrict, reduce, or ban animal testing. A specific pre-clinical trial conducted by the company used 84 mice. While this is for a single trial, it is the only concrete volume provided, falling below the 1,000 animals per year threshold.

Planet-Friendly Business

In 2023, the company's total Scope 1, 2, and 3 greenhouse-gas emissions were 3,450 metric tons, representing a 22.64% reduction from the 2022 baseline of 4,460 metric tons.

The waste diversion rate for research facility waste was 76% in 2023, an increase from 62% in 2022. The company maintained a strong regulatory compliance record with a 92% pass rate on annual compliance audits by the Israel Medical Devices and Diagnostic Regulatory Division.

Safe & Smart Tech

The company's privacy policy states that users can request access, update, or removal of their data, and that data is retained only as needed for specified purposes.

The policy also mentions compliance with applicable laws. However, no further specific details or quantitative evidence are provided regarding the comprehensiveness of user controls, specific data retention periods, or the effectiveness of regulatory compliance.